John Clohessy

John (Seán) Clohessy is director of the Mouse Hospital/Preclinical Murine Pharmacogenetics Facility at the Beth Israel Deaconess Medical Center and Harvard Medical School (BIDMC/HMS) in Boston, Massachusetts. Dr. Clohessy received his Ph.D. in 2005 from University College London, where he studied the role of BCL2 family proteins in the regulation of apoptosis and leukemia. Following this, he completed post-graduate training at Memorial Sloan Kettering Cancer Center and then at the Beth Israel Deaconess Medical School/Harvard Medical School, where he is currently instructor in medicine. His current focus as director of the Mouse Hospital at BIDMC/HMS focuses on the development of best practices approaches for implementation of pre- and co-clinical trials in mice, with the aim to develop a “Mouse Hospital” whereby genetically engineered mouse models that faithfully model human disease can be treated in a manner similar to how they would be treated in human patients. In particular, he is interested in the development and utilization of genetically engineered mouse models for pre- and co-clinical applications to facilitate genetic stratification of patients for focused and rapid clinical evaluation of novel therapies and therapeutic strategies in the treatment of cancer. In addition, Dr. Clohessy has an active research interest in the role of the ribosome and cellular translation in disease.

Education

• Doctor of Philosophy - PhD UCL (1999 — 2005)
• Master of Science - MS Dublin City University (1998 — 1999)
• Bachelor of Science - BS University of Limerick (1994 — 1998)

Companies

• Assistant Professor Harvard Medical School (2021)
• Director, Preclinical Murine Pharmacogenetics Facility Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. (2012)
• Instructor In Medicine Harvard Medical School (2012 — 2021)
• Postdoctoral Research Fellow Beth Israel Deaconess Medical Center (2007 — 2012)
• Postdoctoral Research Fellow Harvard Medical School (2007 — 2012)
• Postdoctoral Fellow Memorial Sloan Kettering Cancer Center (2004 — 2007)